Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Eficácia contra infecção oral persistente, imunogenicidade e segurança da vacina 9-valente contra o papilomavírus humano (9vHPV) em homens de 20 a 45 anos (V503-049)

17 de outubro de 2026 atualizado por: Merck Sharp & Dohme LLC

Um ensaio clínico de fase 3, internacional, multicêntrico, randomizado, duplo-cego e controlado por placebo para estudar a eficácia, a imunogenicidade e a segurança da vacina 9vHPV, uma vacina de partículas semelhantes a vírus L1 multivalente, na prevenção de infecções orais persistentes Infecção pelos tipos de HPV 16, 18, 31, 33, 45, 52 ou 58 em homens adultos, de 20 a 45 anos de idade

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9vHPV vaccine in men 20 to 45 years of age. The primary hypothesis tested after the primary database lock is that administration of a 3-dose regimen of 9vHPV vaccine will reduce the incidence of human papillomavirus (HPV) 16/18/31/33/45/52/58-related oral persistent infection (6 months or longer) compared with placebo.

There will also be an Extension Study to offer an opportunity to complete the 3 dose regimen of 9vHPV vaccine for participants who received placebo in the Base Study, or received less than 3 doses of 9vHPV vaccine in the Base Study.

Visão geral do estudo

Status

Ativo, não recrutando

Tipo de estudo

Intervencional

Inscrição (Real)

6033

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Berlin, Alemanha, 10787
        • Epimed GmbH ( Site 0450)
      • Berlin, Alemanha, 10787
        • Klinische Forschung Berlin ( Site 0454)
      • Hamburg, Alemanha, 20246
        • Universitatsklinikum Hamburg-Eppendorf ( Site 0451)
    • Hesse
      • Frankfurt am Main, Hesse, Alemanha, 60596
        • Infektiologikum Frankfurt-Sachsenhausen ( Site 0456)
      • São Paulo, Brasil, 05402-000
        • Centro de Pesquisa Clinica II - ICHC - FMUSP ( Site 0102)
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil, 40415-006
        • Hospital Santo Antonio - Obras Sociais Irma Dulce ( Site 0101)
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brasil, 59025-050
        • CPCLIN ( Site 0100)
    • Antwerpen
      • Wilrijk, Antwerpen, Bélgica, 2610
        • University of Antwerp ( Site 0352)
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Bélgica, 3000
        • Universitair Ziekenhuis Gasthuisberg ( Site 0353)
      • Tienen, Vlaams-Brabant, Bélgica, 3300
        • Femicare VZW ( Site 0350)
    • Antioquia
      • Medellín, Antioquia, Colômbia, 050021
        • Fundacion Centro de Investigacion Clinica CIC ( Site 0153)
    • Atlántico
      • Barranquilla, Atlántico, Colômbia, 080020
        • Clinica de la Costa Ltda. ( Site 0152)
    • Cundinamarca
      • Chía, Cundinamarca, Colômbia, 250001
        • Centro de Atención e Investigación Médica SAS - CAIMED CHIA ( Site 0156)
      • Seoul, Coréia do Sul, 03312
        • The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 0954)
      • Seoul, Coréia do Sul, 03722
        • Severance Hospital ( Site 0953)
      • Seoul, Coréia do Sul, 07441
        • Hallym University Kangnam Sacred Heart Hospital ( Site 0951)
      • Seoul, Coréia do Sul, 08308
        • Korea University Guro Hospital ( Site 0950)
    • Kyonggi-do
      • Ansan-si, Kyonggi-do, Coréia do Sul, 15355
        • Korea University Ansan Hospital ( Site 0952)
    • Barcelona
      • Badalona, Barcelona, Espanha, 08916
        • Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 0755)
      • Centelles, Barcelona, Espanha, 08540
        • CAP Centelles ( Site 0751)
      • L'Hospitalet de Llobregat, Barcelona, Espanha, 08090
        • ICO L Hospitalet ( Site 0754)
    • California
      • Northridge, California, Estados Unidos, 91325
        • Valley Clinical Trials Inc. ( Site 0002)
      • Rialto, California, Estados Unidos, 92377
        • Inland Empire Clinical Trials, LLC ( Site 0025)
      • Simi Valley, California, Estados Unidos, 93065
        • Alta California Medical Group ( Site 0031)
      • Spring Valley, California, Estados Unidos, 91978
        • Encompass Clinical Research ( Site 0028)
      • Walnut Creek, California, Estados Unidos, 94598
        • Diablo Clinical Research, Inc ( Site 0042)
    • Florida
      • Coral Gables, Florida, Estados Unidos, 33134
        • Clinical Research of South Florida ( Site 0036)
      • Miami, Florida, Estados Unidos, 33142
        • Acevedo Clinical Research Associates ( Site 0001)
      • Tampa, Florida, Estados Unidos, 33617
        • Moffitt Cancer Center ( Site 0017)
    • Georgia
      • Augusta, Georgia, Estados Unidos, 30912
        • Augusta University ( Site 0010)
    • Idaho
      • Meridian, Idaho, Estados Unidos, 83646
        • Solaris Clinical Research, LLC ( Site 0003)
    • Kansas
      • Topeka, Kansas, Estados Unidos, 66606
        • Cotton-O'Neil Clinical Research Center ( Site 0044)
      • Wichita, Kansas, Estados Unidos, 67207
        • Heartland Research Associates, LLC ( Site 0034)
    • Kentucky
      • Bardstown, Kentucky, Estados Unidos, 40004
        • Kentucky Pediatric/Adult Research Inc ( Site 0011)
    • Missouri
      • Hazelwood, Missouri, Estados Unidos, 63042
        • Healthcare Research Network LLC ( Site 0035)
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89119
        • Alliance for Multispecialty Reseach, LLC ( Site 0021)
    • New York
      • Cortland, New York, Estados Unidos, 13045
        • Certified Research Associates ( Site 0041)
      • New York, New York, Estados Unidos, 10011
        • Laser Surgery Care ( Site 0018)
      • New York, New York, Estados Unidos, 10065
        • Weill Cornell Medicine ( Site 0046)
      • Rochester, New York, Estados Unidos, 14609
        • Rochester Clinical Research, Inc. ( Site 0008)
    • North Carolina
      • Salisbury, North Carolina, Estados Unidos, 28144
        • PMG Research of Salisbury ( Site 0009)
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44122
        • Rapid Medical Research, Inc. ( Site 0037)
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15236
        • Preferred Primary Care Physicians ( Site 0032)
    • South Carolina
      • North Charleston, South Carolina, Estados Unidos, 29405
        • Coastal Carolina Research Center ( Site 0043)
    • Tennessee
      • Kingsport, Tennessee, Estados Unidos, 37660
        • Holston Medical Group ( Site 0030)
    • Texas
      • Galveston, Texas, Estados Unidos, 77555-1115
        • University of Texas Medical Branch at Galveston ( Site 0038)
      • Houston, Texas, Estados Unidos, 77081
        • Texas Center For Drug Development ( Site 0013)
      • Victoria, Texas, Estados Unidos, 77901
        • Crossroads Clinical Research LLC ( Site 0027)
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84121
        • J Lewis Research Inc/Foothill Family Clinic South ( Site 0006)
      • South Jordan, Utah, Estados Unidos, 84095
        • J Lewis Research Inc/Jordan River Family Medicine ( Site 0023)
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22911
        • Charlottesville Medical Research Center, LLC ( Site 0007)
      • Newport News, Virginia, Estados Unidos, 23606
        • Health Research of Hampton Roads, Inc. ( Site 0015)
      • Richmond, Virginia, Estados Unidos, 23226
        • Clinical Research Partners, LLC. ( Site 0004)
    • Cote-d Or
      • Dijon, Cote-d Or, França, 21079
        • CHU Dijon Bourgogne - Hopital F. Mitterrand ( Site 0223)
    • Herault
      • Montpellier, Herault, França, 34295
        • Hopital Saint Eloi ( Site 0504)
    • Ille-et-Vilaine
      • Rennes, Ille-et-Vilaine, França, 35033
        • C.H.R.U. de Rennes. Hopital de Pontchaillou ( Site 0507)
    • Loire-Atlantique
      • Nantes, Loire-Atlantique, França, 44093
        • CHU Nantes - Hopital Hotel Dieu ( Site 0510)
    • Île-de-France Region
      • Paris, Île-de-France Region, França, 75014
        • Hopital Cochin ( Site 0506)
      • Haifa, Israel, 3525408
        • Rambam Medical Center ( Site 0601)
      • Jerusalem, Israel, 9112001
        • Hadassah Medical Center. Ein Kerem ( Site 0600)
    • Central District
      • Kfar Saba, Central District, Israel, 4428164
        • Meir Medical Center ( Site 0602)
      • Tel Aviv, Central District, Israel, 6789140
        • Maccabi Health Services Medical Center ( Site 0604)
      • Bari, Itália, 70124
        • Azienda Ospedaliera Policlinico di Bari ( Site 0550)
      • Catania, Itália, 95123
        • AOU Policlinico Vittorio Emanuele ( Site 0552)
      • Roma, Itália, 00161
        • Universita di Roma "La Sapienza" ( Site 0553)
    • Roma
      • Rome, Roma, Itália, 00144
        • Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 0551)
    • Veneto
      • Padova, Veneto, Itália, 35128
        • Azienda Ospedaliera - Universita di Padova ( Site 0555)
      • Fukuoka, Japão, 810-0001
        • Sagiyama Urology Clinic ( Site 1116)
      • Fukuoka, Japão, 812-0025
        • Souseikai PS Clinic ( Site 1103)
      • Kumamoto, Japão, 861-4157
        • Souseikai Nishikumamoto Hospital ( Site 1104)
      • Osaka, Japão, 532-0003
        • Medical Corporation Heishinkai OPHAC Hospital ( Site 1105)
      • Osaka, Japão, 542-0076
        • Nomura Clinic Namba ( Site 1114)
      • Osaka, Japão, 542-0086
        • Medical Corporation Seiwakai Hayakawa Clinic ( Site 1113)
      • Tokyo, Japão, 101-0041
        • Doujin Memorial Medical Foundation, Meiwa Hospital ( Site 1111)
      • Tokyo, Japão, 107-0052
        • Taisei Clinic ( Site 1109)
      • Tokyo, Japão, 144-0051
        • Medical Corporation Mori to Umi Tokyo Tokyo Kamata Hospital ( Site 1112)
      • Tokyo, Japão, 158-0097
        • Naoko Dermatology Clinic ( Site 1107)
      • Tokyo, Japão, 160-0017
        • Medical Corporation Shinanokai Shinanozaka Clinic ( Site 1106)
      • Tokyo, Japão, 160-0022
        • Medical Corporation Iseikai My City Clinic ( Site 1108)
      • Tokyo, Japão, 171-0014
        • Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic ( Site 1102)
      • Tokyo, Japão, 175-0092
        • Kusunoki Clinic ( Site 1110)
    • Tokyo
      • Hachiōji, Tokyo, Japão, 192-0071
        • P-One Clinic, Keikokai Medical Corp. ( Site 1101)
      • Chihuahua City, México, 31000
        • Icaro Investigaciones en Medicina S.A. de C.V. ( Site 0200)
      • Veracruz, México, 91910
        • ARKE Estudios Clinicos S.A de C.V ( Site 0211)
    • Mexico City
      • Mexico City, Mexico City, México, 06700
        • Arke Estudios Clinicos S.A. de C.V. ( Site 0203)
    • Morelos
      • Cuernavaca, Morelos, México, 62100
        • Instituto Nacional de Salud Publica ( Site 0202)
      • Lima, Peru, 07006
        • Policlinico Universidad Nacional Mayor de San Marcos ( Site 0257)
      • Lima, Peru, 15046
        • Investigaciones Medicas en Salud - INMENSA ( Site 0255)
      • Lima, Peru, 15423
        • Instituto de Investigacion Nutricional - Anexo Huascar ( Site 0251)
      • Lima, Peru, LIMA 01
        • Asociacion Via Libre ( Site 0250)
    • Loreto
      • Iquitos, Loreto, Peru, 16000
        • Asociacion Civil Selva Amazonica ( Site 0252)
      • Chiang Mai, Tailândia, 50200
        • Research Institute for Health Sciences ( Site 1053)
    • Bangkok
      • Bangkok, Bangkok, Tailândia, 10400
        • Armed Forces Research Institute of Medical Sciences ( Site 1051)
      • Bangkok, Bangkok, Tailândia, 10400
        • Vaccine Trial Center Faculty of Tropical Medicine ( Site 1052)
      • Bangkok, Bangkok, Tailândia, 10700
        • Faculty of Medicine Siriraj Hospital ( Site 1050)
      • Kaohsiung City, Taiwan, 833
        • Chang Gung Medical Foundation. Kaohsiung Branch ( Site 1003)
      • Tainan, Taiwan, 70403
        • National Cheng Kung University Hospital ( Site 1002)
      • Taipei, Taiwan, 100
        • National Taiwan University Hospital ( Site 1000)
      • Taoyuan, Taiwan, 333
        • Chang Gung Medical Foundation.Linkou Branch ( Site 1001)
      • Olomouc, Tcheca, 772 00
        • G-CENTRUM Olomouc s.r.o. ( Site 0400)
      • Prague, Tcheca, 120 00
        • MediStar s.r.o. ( Site 0403)
      • Prague, Tcheca, 150 06
        • FN Motol ( Site 0402)
    • Brno-mesto
      • Brno, Brno-mesto, Tcheca, 602 00
        • Centrum ambulantni gynekologie a primarni pece ( Site 0401)

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

20 anos a 45 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Macho

Descrição

Inclusion Criteria:

Base Study:

  • Is healthy and is judged to be in good physical health based on medical history and physical examination
  • Has provided written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research
  • Agrees to provide study personnel with a primary telephone number as well as an alternate means of contact, if available (such as an alternate telephone number or email) for follow-up purposes
  • Can read, understand, and complete the electronic vaccination report card (eVRC)
  • Has had at least 1 lifetime sexual partner

Extension Study:

  • Participants may continue in the Extension Study if Inclusion Criteria #1 and #4 are still met, and the participants was in either the placebo group in the Base Study or the vaccine group in the Base Study but did not complete the vaccination series
  • Provides documented consent for the Extension Study

Exclusion Criteria:

Base Study:

  • Has a history of HPV-related anal lesion (anal intraepithelial neoplasia or anal cancer) or HPV related head and neck cancer
  • Has a history of or clinical evidence at the Day 1 external genital examination of HPV-related external lesion
  • Has clinical evidence at the Day 1 external genital examination of gross genital lesion suggesting sexually transmitted disease
  • Has a fever (defined as oral temperature ≥100.0°F or ≥37.8°C) within a 24-hour period prior to Day 1 visit
  • Has a history of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention
  • Is allergic to any vaccine component, including aluminum, yeast, or BENZONASE®
  • Has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
  • Is currently immunocompromised or has been diagnosed as having congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition
  • Has a history of splenectomy
  • Has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate by judgment of investigator
  • Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence at the discretion of the investigator. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems because of alcohol use
  • Has received within 12 months prior to enrollment, is receiving, or plans to receive during the study, the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (ARAVA®), TNF-α antagonists, monoclonal antibody therapies (including rituximab [RITUXAN®]), intravenous immunoglobulin (IVIG), anti-lymphocyte sera, or other therapy known to interfere with the immune response. Regarding systemic corticosteroids, a participant will be excluded if he is currently receiving steroid therapy, has recently received such therapy, or has received 2 or more courses of high-dose corticosteroids (≥20 mg/day of prednisone [or equivalent] orally or parenterally) lasting at least 1 week in duration in the year prior. Participants using inhaled, nasal, or topical steroids are considered eligible for the study
  • Has received within the 3 months prior to vaccination, is receiving, or plans to receive during the study, any immune globulin product (including RhoGAM™) or blood-derived product other than IVIG
  • Has received inactivated or recombinant vaccines within 14 days prior to vaccination or receipt of live vaccines within 21 days prior to vaccination
  • Is concurrently enrolled in other clinical studies of investigational agents
  • Has previously received a marketed HPV vaccine, or has participated in a clinical trial for any HPV vaccine (receiving either active agent or placebo)
  • Has engaged in sexual activity 48 hours prior to vaccination. Sexual activity is defined as: penile penetrative vaginal intercourse with female partner; penile penetrative or receptive anal intercourse with male or female partner; or oral sex involving any contact between participant's mouth with a female partner's vagina, genital or anal area or male partner's penis or genital or anal area. This also includes any contact between participant's partner's mouth with participant's penis, genital or anal area
  • Is unlikely to adhere to the study procedures, keep appointments, or is planning to permanently relocate from the area prior to the completion of the study or to leave for an extended period when study visits would need to be scheduled
  • Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study

Extension Study:

- Participants must be excluded from the Extension Study if Base Study Exclusion Criteria #4, 5, 6, 7, 10, 16, or 18 are met

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: 9vHPV vaccine

Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6

9vHPV is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.

Outros nomes:
  • GARDASIL®9
  • V503
Comparador de Placebo: Placebo

Single 0.5-mL intramuscular injection at Day 1, Month 2, and Month 6

0.9% sodium chloride given as a 0.5-mL intramuscular injection

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of HPV 16/18/31/33/45/52/58-related 6-month Persistent Oral Infection
Prazo: Up to Month 90

A 6-month persistent infection is defined to have occurred if a participant, after completion of the Month 7 visit, is positive for the same HPV type by the HPV polymerase chain reaction (PCR) assay to at least 1 common gene in Oral Rinse and Gargle (ORG) samples obtained at 2 or more consecutive visits at 6 months (+/-1 month visit window) apart.

Up to Month 90

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Incidence of HPV 6/11-related 6-month Persistent Oral Infection
Prazo: Up to Month 90

A 6-month persistent infection is defined to have occurred if a participant, after completion of the Month 7 visit, is positive for the same HPV type by the HPV PCR assay to at least 1 common gene in ORG samples obtained at 2 or more consecutive visits at 6 months (+/-1 month visit window) apart.

Up to Month 90
Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 Antibodies
Prazo: 1 month postdose 3 (Month 7)

Serum antibodies to HPV types are measured with competitive Luminex immunoassay (cLIA). Geometric mean titers of antibodies to HPV types will be calculated by exponentiating the mean estimates of natural logarithm of the anti-HPV titers.

1 month postdose 3 (Month 7)
Percentage of Participants who Seroconvert to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Prazo: 1 month postdose 3 (Month 7)

Seroconversion is defined as changing a participant's serostatus from seronegative at Day 1 to seropositive by 4 weeks postdose 3. A participant with anti-HPV cLIA titer at or above the serostatus cutoff of the cLIA for a given HPV type is considered seropositive for that HPV type.

1 month postdose 3 (Month 7)
Percentage of Participants with at Least 1 Solicited Injection-site Adverse Event (AE)
Prazo: Up to 5 days after any vaccination

An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Solicited injection-site AEs such as redness/erythema, swelling, and tenderness/pain at the injection site will be recorded.

Up to 5 days after any vaccination
Percentage of Participants with Elevated Temperature (Fever)
Prazo: Up to 5 days after any vaccination

Participants are asked to record oral body temperatures. The percentage of participants with elevated temperature (≥37.8°C or 100.0°F) will be assessed.

Up to 5 days after any vaccination
Percentage of Participants Who Report at Least 1 Systemic AE
Prazo: Up to 15 days after any vaccination

An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study vaccine. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study vaccine or protocol-specified procedure is also an AE. Systemic AEs are those not categorized as injection-site AEs.

Up to 15 days after any vaccination
Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)
Prazo: Up to 15 days after any vaccination

A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is another important medical event deemed such by medical or scientific judgment.

Up to 15 days after any vaccination
Percentage of Participants who Experience at Least 1 Serious Vaccine-Related AE
Prazo: Up to Month 90

A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is another important medical event deemed such by medical or scientific judgment. An SAE that is considered by an investigator (a qualified physician) to be vaccine-related will be reported during entire study period.

Up to Month 90

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Medical Director, Merck Sharp & Dohme LLC

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

27 de fevereiro de 2020

Conclusão Primária (Estimado)

15 de janeiro de 2027

Conclusão do estudo (Estimado)

13 de agosto de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

12 de dezembro de 2019

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de dezembro de 2019

Primeira postagem (Real)

16 de dezembro de 2019

Atualizações de registro de estudo

Última Atualização Postada (Real)

20 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • V503-049
  • V503-049 (Outro identificador: MSD)
  • 205346 (Identificador de registro: JAPIC-CTI)
  • U1111-1275-8682 (Identificador de registro: UTN)
  • 2019 (Concessão/Contrato do NIH dos EUA)
  • 2022-501974-21-00 (Identificador de registro: EU CT)
  • 2019-003236-23 (Número EudraCT)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever